For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for incident diabetic retinopathy (DR) and with a ...

The latest results from a trial of a pill form popular GLP-1 medications offer enough information for the Eli Lilly to request global regulatory approval this year, the company said Tuesday.

Serena Williams sparked a heated debate after revealing she lost 31 pounds using a GLP-1 drug. While the tennis legend ...

In Australia, Ozempic is registered for type 2 diabetes, not weight loss. A higher-dose brand, Wegovy, is registered for ...

Eli Lilly stated that results from a late-stage trial of its pill variant of GLP-1 drugs met the requirements for global ...

Eli Lilly (NYSE:LLY) announced on Tuesday that its oral weight loss therapy, orforglipron, reached the main goals in a second ...

With around 73 percent of Americans enjoying their daily coffee fix, it’s natural to wonder how your morning cup might ...

Eli Lilly said its once-daily weight loss pill was effective for people with obesity and type 2 diabetes in a key trial, ...

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for ...

A groundbreaking final stage trial showed users could lose more than 10 per cent of their weight after just over a year on ...

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced its participation in upcoming investor and industry conferences.